Sign In
Buy OVID
$2.40
-0.0800 (-3.23%)
At Close: Jun 05, 2026
Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm
11:00am, Saturday, 17'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeut
Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm
11:00am, Friday, 16'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeut
Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm
11:00am, Thursday, 15'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeut
Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm
10:30pm, Wednesday, 14'th Aug 2024
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID
Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm
01:15am, Wednesday, 14'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeut
Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates
10:10am, Tuesday, 13'th Aug 2024
Ovid Therapeutics (OVID) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to loss of $0.18 per share a year ago.
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
08:00am, Tuesday, 13'th Aug 2024
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditio
Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm
11:55pm, Monday, 12'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeut
Investors Of Ovid Therapeutics Inc Can Participate In Fraud Investigation With The Schall Law Firm
09:15pm, Friday, 09'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeuti
Investors Of Ovid Therapeutics Inc Eligible To Join Fraud Investigation With The Schall Law Firm
04:00pm, Thursday, 08'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeuti
Investors Of Ovid Therapeutics Inc Can Join Fraud Investigation With The Schall Law Firm
11:30pm, Wednesday, 07'th Aug 2024
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID
Ovid Therapeutics Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm
04:00pm, Tuesday, 06'th Aug 2024
LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeuti
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVID
04:18pm, Saturday, 03'rd Aug 2024
NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ovid Therapeutics Inc. (“Ovid” or the “Company”) (NASDAQ: OVID). Such investors are
OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm
10:00am, Friday, 02'nd Aug 2024
LOS ANGELES , Aug. 2, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics In
OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm
07:56pm, Thursday, 01'st Aug 2024
LOS ANGELES--(BUSINESS WIRE)--OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm.
